Literature DB >> 26598946

Computational oncology--mathematical modelling of drug regimens for precision medicine.

Dominique Barbolosi1, Joseph Ciccolini1, Bruno Lacarelle1, Fabrice Barlési1,2,3, Nicolas André4,5,3.   

Abstract

Computational oncology is a generic term that encompasses any form of computer-based modelling relating to tumour biology and cancer therapy. Mathematical modelling can be used to probe the pharmacokinetics and pharmacodynamics relationships of the available anticancer agents in order to improve treatment. As a result of the ever-growing numbers of druggable molecular targets and possible drug combinations, obtaining an optimal toxicity-efficacy balance is an increasingly complex task. Consequently, standard empirical approaches to optimizing drug dosing and scheduling in patients are now of limited utility; mathematical modelling can substantially advance this practice through improved rationalization of therapeutic strategies. The implementation of mathematical modelling tools is an emerging trend, but remains largely insufficient to meet clinical needs; at the bedside, anticancer drugs continue to be prescribed and administered according to standard schedules. To shift the therapeutic paradigm towards personalized care, precision medicine in oncology requires powerful new resources for both researchers and clinicians. Mathematical modelling is an attractive approach that could help to refine treatment modalities at all phases of research and development, and in routine patient care. Reviewing preclinical and clinical examples, we highlight the current achievements and limitations with regard to computational modelling of drug regimens, and discuss the potential future implementation of this strategy to achieve precision medicine in oncology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26598946     DOI: 10.1038/nrclinonc.2015.204

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  111 in total

1.  Mathematics and oncology: a match for life?

Authors:  Martine J Piccart-Gebhart
Journal:  J Clin Oncol       Date:  2003-02-13       Impact factor: 44.544

Review 2.  Covariate pharmacokinetic model building in oncology and its potential clinical relevance.

Authors:  Markus Joerger
Journal:  AAPS J       Date:  2012-01-25       Impact factor: 4.009

3.  Modeling intrinsic heterogeneity and growth of cancer cells.

Authors:  James M Greene; Doron Levy; King Leung Fung; Paloma S Souza; Michael M Gottesman; Orit Lavi
Journal:  J Theor Biol       Date:  2014-11-29       Impact factor: 2.691

4.  Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach.

Authors:  Brian Higgins; Kelli Glenn; Antje Walz; Christian Tovar; Zoran Filipovic; Sazzad Hussain; Edmund Lee; Kenneth Kolinsky; Shahid Tannu; Violeta Adames; Rosario Garrido; Michael Linn; Christophe Meille; David Heimbrook; Lyubomir Vassilev; Kathryn Packman
Journal:  Clin Cancer Res       Date:  2014-05-08       Impact factor: 12.531

5.  Mathematical modeling of folate metabolism.

Authors:  John C Panetta; Steven W Paugh; William E Evans
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2013-05-22

Review 6.  New paradigms for treating elderly patients with cancer: the comprehensive geriatric assessment and guidelines for supportive care.

Authors:  Lodovico Balducci
Journal:  J Support Oncol       Date:  2003 Nov-Dec

7.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

8.  Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model.

Authors:  O Vainas; S Ariad; O Amir; W Mermershtain; V Vainstein; M Kleiman; O Inbar; R Ben-Av; A Mukherjee; S Chan; Z Agur
Journal:  Br J Cancer       Date:  2012-07-19       Impact factor: 7.640

Review 9.  The growth rate of human tumours.

Authors:  G G Steel; L F Lamerton
Journal:  Br J Cancer       Date:  1966-03       Impact factor: 7.640

10.  Classical mathematical models for description and prediction of experimental tumor growth.

Authors:  Sébastien Benzekry; Clare Lamont; Afshin Beheshti; Amanda Tracz; John M L Ebos; Lynn Hlatky; Philip Hahnfeldt
Journal:  PLoS Comput Biol       Date:  2014-08-28       Impact factor: 4.475

View more
  52 in total

Review 1.  Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.

Authors:  Guido Bocci; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2016-05-17       Impact factor: 66.675

Review 2.  Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.

Authors:  Clara Hartmanshenn; Megerle Scherholz; Ioannis P Androulakis
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-09-19       Impact factor: 2.745

Review 3.  Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues.

Authors:  Aleksandra Karolak; Dmitry A Markov; Lisa J McCawley; Katarzyna A Rejniak
Journal:  J R Soc Interface       Date:  2018-01       Impact factor: 4.118

Review 4.  The extracellular matrix as a key regulator of intracellular signalling networks.

Authors:  Jordan F Hastings; Joanna N Skhinas; Dirk Fey; David R Croucher; Thomas R Cox
Journal:  Br J Pharmacol       Date:  2018-04-19       Impact factor: 8.739

Review 5.  Oncological Ligand-Target Binding Systems and Developmental Approaches for Cancer Theranostics.

Authors:  Jaison Jeevanandam; Godfred Sabbih; Kei X Tan; Michael K Danquah
Journal:  Mol Biotechnol       Date:  2021-01-09       Impact factor: 2.695

Review 6.  New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.

Authors:  Joakim Crona; David Taïeb; Karel Pacak
Journal:  Endocr Rev       Date:  2017-12-01       Impact factor: 19.871

7.  Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxel.

Authors:  Hua He; Yanguang Cao
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-08-31       Impact factor: 2.745

8.  Modular Fabrication of Intelligent Material-Tissue Interfaces for Bioinspired and Biomimetic Devices.

Authors:  John R Clegg; Angela M Wagner; Su Ryon Shin; Shabir Hassan; Ali Khademhosseini; Nicholas A Peppas
Journal:  Prog Mater Sci       Date:  2019-07-17

9.  Pharmacokinetic/pharmacodynamic modeling of combination-chemotherapy for lung cancer.

Authors:  Louis T Curtis; Victor H van Berkel; Hermann B Frieboes
Journal:  J Theor Biol       Date:  2018-04-01       Impact factor: 2.691

10.  Modeling of Combination Chemotherapy and Immunotherapy for Lung Cancer.

Authors:  Louis T Curtis; Hermann B Frieboes
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2019-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.